Abstract
Recent research on histamine H2 receptor agonists was focused on quantitative structure-activity relationships and receptor models explaining the activity of imidazolylpropylguanidines. Their selectivity for guinea pig vs. human isoforms was investigated using H2 receptor-Gsα fusion proteins and attributed to amino acid differences in transmembrane domains 1 and 7. New antagonists result from approaches to improve pharmacokinetic properties and to design hybrid drugs which additionally have gastroprotective or anti H. pylori activity.
Keywords: h2 receptor agonists, h2 receptor antagonists, impromidine analogues, arpromidine, molecular modelling, structure-activity relationships, qsar, site-directed mutagenesis
Mini-Reviews in Medicinal Chemistry
Title: Structure-Activity Relationships of Histamine H2 Receptor Ligands+
Volume: 4 Issue: 9
Author(s): Stefan Dove, Sigurd Elz, Roland Seifert and Armin Buschauer
Affiliation:
Keywords: h2 receptor agonists, h2 receptor antagonists, impromidine analogues, arpromidine, molecular modelling, structure-activity relationships, qsar, site-directed mutagenesis
Abstract: Recent research on histamine H2 receptor agonists was focused on quantitative structure-activity relationships and receptor models explaining the activity of imidazolylpropylguanidines. Their selectivity for guinea pig vs. human isoforms was investigated using H2 receptor-Gsα fusion proteins and attributed to amino acid differences in transmembrane domains 1 and 7. New antagonists result from approaches to improve pharmacokinetic properties and to design hybrid drugs which additionally have gastroprotective or anti H. pylori activity.
Export Options
About this article
Cite this article as:
Dove Stefan, Elz Sigurd, Seifert Roland and Buschauer Armin, Structure-Activity Relationships of Histamine H2 Receptor Ligands+, Mini-Reviews in Medicinal Chemistry 2004; 4 (9) . https://dx.doi.org/10.2174/1389557043403242
DOI https://dx.doi.org/10.2174/1389557043403242 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Preparation of Therapeutic Dose of <sup>177</sup>Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy
Current Radiopharmaceuticals Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Toxicity and Tolerability of <sup>177</sup>Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study
Current Radiopharmaceuticals Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry